RITALIN

Methylphenidate has robust clinical evidence for treating ADHD in both children and adults, with extended-release formulations demonstrating efficacy in once-daily dosing regimens. Clinical trials show significant improvement in inattention and hyperactivity symptoms compared to placebo. It has also been explored in neurological populations for post-stroke depression and traumatic brain injury recovery, though evidence in these areas remains limited and inconclusive. Animal studies indicate that co-administration with SSRIs may potentiate addiction-related gene regulation in the striatum, raising concerns about combined use. Abuse and diversion are well-documented, particularly when used outside prescribed parameters or via insufflation.